Overview

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Status:
Recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Lenvatinib